CTLA4 and cancer: Moreover, antibodies targeting the immune checkpoint molecules PD-1, PD-L1, and cytotoxic T-lymphocyte antigen 4 (CTLA-4), administered alone or in combination with chemotherapy, are the standard of care in most patients with metastatic non-small cell lung cancers and other cancers [103,104].